Fortrea Completes Expansion of Clinical Pharmacology Solutions With Targeted Investment in Four Clinical Research Sites in US and UK
Saturday, November 04, 2023
Fortrea (Nasdaq: FTRE), a world leader in commissioned research, today announced that after years of hard work, it has completed clinical pharmacology solutions and manufacturing capabilities The extension is now fully available to customers. The expansion includes a 100,000-square-foot state-of-the-art facility in Leeds, England, as well as approximately 20,000 square feet of new or renovated space, adding clinical facilities in Dallas, Texas; Daytona Beach, Florida; and Madison, Wisconsin. Research unit (CRU) production capacity and treatment capabilities.
The increasing complexity of clinical pharmacology studies requires the infrastructure, experience and expertise that is fit for purpose to ensure the safety of study participants and, above all, the integrity of data," said Fortrea's President of Clinical Pharmacology and Chief Medical Officer Oren Cohen, Ph.D. said. "Our integrated service platform includes state-of-the-art infrastructure and experienced professionals including physicians, nurses, clinical scientists, clinical research coordinators and pharmacokineticists who are fully committed to clinical Pharmacological research. The investments we make are designed to deliver the therapeutic capabilities and manufacturing capabilities our customers need to accurately evaluate early-stage drug candidates and rapidly advance those promising drugs into later-stage development, ultimately making them available to the patients who need them. "
Among the completed expansions, facility improvements involve Fortrea's new clinical research unit in Leeds, as well as purpose-built rooms in Madison and Daytona Beach designed to conduct early-stage complex clinical studies. In addition, facility improvements to recreational, residential and "telework" spaces at Fortrea's clinical research units have been completed to enhance the experience of study volunteers at these sites.
Expansions to Fortrea's early clinical development pharmacy services include new cGMP pharmacies at clinical research units in Leeds and Daytona Beach. All Fortrea clinical research units will now have on-site cGMP pharmacies. As a result, sterile and non-sterile pharmaceutical products can now be manufactured on-site. Its GMP-compliant facility design provides for the safe handling and delivery of pharmaceutical products in compliance with GMP quality standards, meeting the unique needs of various clinical pharmacology studies, focusing on efficiency and flexibility, and its level of control expected by regulatory agencies and sponsors. within.
Improvements in science and technology include the addition of artificial intelligence-based procedures to optimize bed utilization and treatment scheduling, and the application of failure mode and impact analysis to reduce risks to study execution before the study begins. After investing in a data collection system, all clinical pharmacology study data collected by Fortrea's clinical research units are fed directly into a digital point-of-care data collection system, which also serves as an efficient electronic data capture solution.
"I believe Fortrea's early clinical development solutions set a new standard for what the clinical research industry should expect from its partners," said Dr. Cohen. “I’m extremely proud of this team and know they, too, will benefit from the changes we’re making. Just as they are inspired by our mission to get patients treatments faster that can dramatically improve their lives, we I am inspired by the dedication they show every day as they deliver solutions for our customers."
About Fortrea
Fortrea (Nasdaq: FTRE) is a global leader in clinical development solutions and patient access solutions for the life sciences industry. We work with large emerging biopharmaceutical, medical device and medical diagnostics companies to drive medical innovation to more quickly get treatments that dramatically improve the lives of patients in need. Fortrea provides Phase I to IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services.
Fortrea's solutions integrate more than three decades of experience across more than 20 therapeutic areas, emphasizing scientific rigor, deep insights and a strong network of researchers and research centers. With more than 19,000 talented and diverse team members working in more than 90 countries, we provide professional and flexible solutions to customers around the world.
To learn more about how Fortrea is a transformative force from drug discovery to patient use, visit Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release, particularly those relating to expected financial and other benefits, including, but not limited to, whether investments in clinical research units in the United States and the United Kingdom will increase production capacity, improve treatment capabilities, enhance the research volunteer experience, Expediting subsequent trials and increasing data integrity, as well as whether artificial intelligence-enabled procedures will optimize bed utilization and clinical scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the company's control. If one or more of these underlying assumptions or expectations prove inaccurate or fail to materialize, actual results may differ materially from the expectations expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from such expectations will be described in Fortrea's Registration Statement on Form 10 (as amended and further supplemented) initially filed with the SEC on May 15, 2023, and Fortrea's registration statement on August 20, 2023. Details are provided in Fortrea's quarterly report on Form 10-Q filed with the SEC on March 14, as well as other filings Fortrea filed with the SEC. These forward-looking statements are based on management's current expectations and are subject to certain risks, uncertainties and changes in circumstances. Fortrea undertakes no duty to update these statements, which speak only as of the date of this release.
Fortrea contact details:
Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva @fortrea.com
Source: globenewswire.com
